Scarica l'app Stockscreener
23.59
0.85%
0.1686
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché ARQT Giù?
Forum
Previsione
Precedente Chiudi:
$23.42
Aprire:
$23.81
Volume 24 ore:
130.17K
Relative Volume:
0.10
Capitalizzazione di mercato:
$2.95B
Reddito:
$376.07M
Utile/perdita netta:
$-16.14M
Rapporto P/E:
-168.61
EPS:
-0.1399
Flusso di cassa netto:
$-16.31M
1 W Prestazione:
+5.59%
1M Prestazione:
-0.15%
6M Prestazione:
-5.90%
1 anno Prestazione:
+64.94%
Intervallo 1D:
$23.25
$23.82
Intervallo di 1 settimana:
$22.47
$24.03
Portata 52W:
$12.42
$31.77
Arcutis Biotherapeutics Inc Stock (ARQT) Company Profile
Nome
Arcutis Biotherapeutics Inc
Settore
Industria
Telefono
805-418-5006
Indirizzo
3027 TOWNSGATE ROAD, WESTLAKE VILLAGE, CA
Compare ARQT vs VRTX, REGN, ARGX, ALNY, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ARQT
Arcutis Biotherapeutics Inc
|
23.59 | 2.93B | 376.07M | -16.14M | -16.31M | -0.1399 |
VRTX
Vertex Pharmaceuticals Inc
|
428.60 | 107.87B | 12.32B | 4.34B | 3.19B | 16.86 |
REGN
Regeneron Pharmaceuticals Inc
|
718.27 | 73.63B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
811.52 | 49.42B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
304.15 | 40.20B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
312.07 | 33.06B | 5.36B | 287.73M | 924.18M | 2.5229 |
Arcutis Biotherapeutics Inc Stock (ARQT) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-07-25 | Iniziato | Goldman | Neutral |
| 2024-12-30 | Iniziato | H.C. Wainwright | Buy |
| 2024-08-28 | Iniziato | Jefferies | Buy |
| 2024-01-03 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-26 | Downgrade | Mizuho | Buy → Neutral |
| 2023-10-13 | Downgrade | Goldman | Buy → Neutral |
| 2022-09-07 | Iniziato | Needham | Buy |
| 2022-03-17 | Iniziato | Goldman | Buy |
| 2021-06-30 | Iniziato | Mizuho | Buy |
| 2021-05-27 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2020-11-09 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-10-08 | Iniziato | Truist | Buy |
| 2020-02-25 | Iniziato | Cantor Fitzgerald | Overweight |
| 2020-02-25 | Iniziato | Cowen | Outperform |
| 2020-02-25 | Iniziato | Goldman | Neutral |
| 2020-02-25 | Iniziato | Guggenheim | Buy |
Mostra tutto
Arcutis Biotherapeutics Inc Borsa (ARQT) Ultime notizie
Arcutis director Howard Welgus sells $164,219 in company stock - Investing.com
Arcutis director Howard Welgus sells $164,219 in company stock By Investing.com - Investing.com UK
Arcutis Biotherapeutics (ARQT) director sells 7,144 shares under 10b5-1 plan - Stock Titan
Director sale: Arcutis Biotherapeutics (NASDAQ: ARQT) plans to sell 684 shares - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) files to sell 1,341 vested shares via Merrill Lynch - Stock Titan
3,172-Share Form 144 Filed by Arcutis Biotherapeutics (NASDAQ: ARQT) - Stock Titan
Arcutis Biotherapeutics (NASDAQ: ARQT) reports vesting and insider sales in Form 144 - Stock Titan
UBS Group AG Boosts Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Kornitzer Capital Management Inc. KS Takes Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Howard Welgus sells 30,000 ARQT shares (NASDAQ: ARQT) across three dates - Stock Titan
Will Arcutis Biotherapeutics, Inc. (ARQT) report negative earnings next week? What you should know - MSN
Jennison Associates LLC Has $196.25 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Will Arcutis Biotherapeutics, Inc. (ARQT) Report Negative Earnings Next Week? What You Should Know - Yahoo Finance
Arcutis Biotherapeutics (ARQT) Expected to Announce Earnings on Wednesday - MarketBeat
Universal Beteiligungs und Servicegesellschaft mbH Buys 147,586 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Calamos Advisors LLC Takes $1.57 Million Position in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis submits application to expand Zoryve use to infants - Investing.com UK
Arcutis Biotherapeutics (ARQT) Expands Zoryve Cream Application for Infants - GuruFocus
Arcutis submits sNDA for roflumilast cream 0.05% in atopic dermatitis for infants down to 3 months - Contemporary Pediatrics
Arcutis submits application to expand Zoryve use to infants By Investing.com - Investing.com South Africa
Arcutis Submits Supplemental New Drug Application to the FDA for ZORYVE® (roflumilast) Cream 0.05% to Expand Indication for Treatment of Atopic Dermatitis to Infants Down to 3 Months - The Manila Times
FDA filing targets eczema treatment for babies as young as 3 months - Stock Titan
ARQT Stock Price, Quote & Chart | ARCUTIS BIOTHERAPEUTICS INC (NASDAQ:ARQT) - ChartMill
Q4 2025 Arcutis Biotherapeutics Inc Earnings Call Transcript - GuruFocus
A Look At Arcutis Biotherapeutics (ARQT) Valuation After Recent Share Price Moves - Yahoo Finance
How The Arcutis Biotherapeutics (ARQT) Narrative Is Shifting Around Zoryve And The $35 Target - Yahoo Finance
TD Cowen Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Analysts Offer Insights on Healthcare Companies: Alto Neuroscience, Inc. (ANRO), Arcutis Biotherapeutics (ARQT) and Valneva (VALN) - The Globe and Mail
ARQT (Arcutis Biotherapeutics Inc.) tops Q4 2025 EPS estimates on 91 percent year over year revenue growth, shares slip 2.03 percent.Crowd Risk Alerts - UBND thành phố Hải Phòng
Is Arcutis (ARQT) stock building trend strength (Investor Interest) 2026-04-22Crowd Sentiment Stocks - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis’ ZORYVE® (roflumilast) Cream Receives Strong Recommendation in American Academy of Dermatology First-Ever Pediatric Atopic Dermatitis Guidelines - The Manila Times
AAD backs steroid-free ZORYVE for children with eczema - Stock Titan
Morgan Stanley Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
[ARS] Arcutis Biotherapeutics, Inc. SEC Filing - Stock Titan
Arcutis Biotherapeutics (ARQT) 2026 proxy details votes on board, pay and auditor - Stock Titan
Is Arcutis (ARQT) stock losing support (Slight Loss) 2026-04-20Collaborative Trading Signals - Cổng thông tin điện tử Tỉnh Sơn La
Arcutis Biotherapeutics (ARQT) Presents Positive Phase 2 Data for ZORYVE Cream in Infants - Insider Monkey
5 Overlooked Growth Stocks to Buy Now - Insider Monkey
Phocas Financial Corp. Trims Stake in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis to Report First Quarter 2026 Financial Results and Host Conference Call on May 6, 2026 - The Manila Times
Needham Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $36 - Moomoo
Arcutis to give business update with Q1 results after market close May 6 - Stock Titan
Arcutis Biotherapeutics (ARQT) price target increased by 10.24% to 35.70 - MSN
Arcutis Biotherapeutics Targets ZORYVE Expansion, Raises 2026 Outlook and Turns Cash-Flow Positive - Yahoo Finance
Tudor Investment Corp ET AL Makes New Investment in Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Arcutis Biotherapeutics Inc (NASDAQ:ARQT) Emerges as a High-Growth Momentum Breakout Candidate - ChartMill
(ARQT) and the Role of Price-Sensitive Allocations - Stock Traders Daily
AMI Asset Management Corp Sells 46,829 Shares of Arcutis Biotherapeutics, Inc. $ARQT - MarketBeat
Mizuho Securities Maintains Arcutis Biotherapeutics(ARQT.US) With Buy Rating, Maintains Target Price $35 - Moomoo
Arcutis (ARQT) announces long-term phase 3 data for ZORYVE cream in children - MSN
Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
Arcutis Biotherapeutics Inc Azioni (ARQT) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.78%
3.01%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):